Management of Non-Occlusive Femoral DVT with Severe Anemia

Immediate Actions

The American College of Cardiology recommends that the combination of anticoagulation and antiplatelet therapy significantly increases major bleeding risk, and with hemoglobin of 7.7 g/dL, the bleeding risk outweighs any cardiovascular benefit from aspirin in this acute setting 1
The combination of aspirin and apixaban dramatically increases bleeding risk, particularly in the setting of severe anemia 1
Critically reassess whether there is an absolute indication for aspirin, and if no compelling cardiovascular indication exists, aspirin should remain discontinued 1

The American Heart Association suggests that only continue aspirin if there is a recent acute coronary event or coronary intervention requiring dual antiplatelet therapy 1
Apixaban is preferred over warfarin for DVT treatment and does not require bridging with parenteral anticoagulation 2
The American College of Chest Physicians recommends that the femoral vein location qualifies as proximal DVT requiring full anticoagulation regardless of whether it is occlusive or non-occlusive 3, 4

The American College of Cardiology recommends continuing therapeutic anticoagulation for a minimum of 3 months for the acute DVT treatment phase 1, 2
After 3 months, reassess for extended anticoagulation based on whether DVT was provoked or unprovoked 1, 2

The American College of Chest Physicians recommends that non-occlusive DVT in the femoral vein still requires full therapeutic anticoagulation to prevent extension and pulmonary embolism 3, 4
Catheter-directed thrombolysis is NOT indicated for non-occlusive femoral DVT with mild-moderate symptoms 2, 5
The Journal of the American College of Radiology suggests that thrombolysis should be reserved for limb-threatening DVT or highly symptomatic iliofemoral DVT in young patients with low bleeding risk 2, 5